Periodic Reporting for period 1 - FACTs (Fast Acting Virus Control Strategies for Production Animal Diseases)
Reporting period: 2015-05-01 to 2015-10-31
Investigations into unmet needs of the livestock industry resulted in the addition of 6 new product candidates to ViroVet’s portfolio, ensuring a healthy pipeline.
The refined business plan was the basis of ViroVet’s incorporation on July 30th, 2015 as a separate legal entity. ViroVet management is now in advanced discussions with potential lead and co-lead investors with the aim to close a series A round in early 2016.
ViroVet’s livestock solutions will create a healthy company that aids in battling some societal issues of our time:
• Global human population growth drives animal-based protein needs. Reducing the burden of viral disease will provide healthier livestock and better performing production systems.
• Antibiotic use will be decreased as ViroVet’s technologies will better protect livestock from viral disease and associated bacterial infections, reducing the risk for antimicrobial resistance through overuse/misuse in veterinary practice.
• Some of ViroVet’s products are aimed at controlling infectious diseases at source (e.g. by addressing African/Asian markets) thereby reducing the risk of spread as a result of climate change.
ViroVet intends to apply for an SME Instrument Phase 2 to support full introduction of the BVD product.